Med. praxi. 2016;13(2):75-78 | DOI: 10.36290/med.2016.016

Multiple sclerosis: Treating and managing fatigue

doc.MUDr.Martin Vališ, Ph.D., MUDr.Zbyšek Pavelek, doc.MUDr.Jiří Masopust, Ph.D.
Neurologická klinika LF a FN Hradec Králové

Multiple sclerosis (MS) is a chronic inflammatory disease which is characterized by infiltration of leukocytes into the central nervous

system. This situation leads to the destruction of myelin and to the loss of axons and olidendrocytes. MS is an autoimmune

disease and the most common cause of neurologic disability in young and middle-aged adults. Fatigue, one of the most common

symptoms of MS, may lead to a shortened or decreased quality of life. The cause of fatigue is not clear but probably multifactorial.

Diagnosis of fatigue and its quantification is very difficult.

Keywords: multiple sclerosis, fatigue, treatment

Published: May 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vališ M, Pavelek Z, Masopust J. Multiple sclerosis: Treating and managing fatigue. Med. praxi. 2016;13(2):75-78. doi: 10.36290/med.2016.016.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Krejsek J. Novinky v patogenezi roztroušené sklerózy. Co je skryto za disabilitou pacientů s RS, Remedia 2014: S2-4.
    2. Steinman L. Multiple sclerosis: a two-stage disease. Nature Immunol. 2001; 2(9): 762-764. Go to original source... Go to PubMed...
    3. Holick FM. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80: 1678S-1688S. Go to original source...
    4. Salzer J, Hallmans G, Nyström M, Stenlund H, Wadell G, Sundström P. Vitamin D as a protective factor in multiple sclerosis. Neurology 2012 Nov 20; 79(21): 2140-2145. Go to original source...
    5. Pohl D, Krone K, Rostasy K, Kahler E, Brunner E, Lehnert M, Wagner HJ, Gärtner J, Hanefeld F High Seroprevalence of Epstein-Barr Virus in Children with Multiple Sclerosis. Neurology 2006; 67: 2063-2065. Go to original source...
    6. Colosimo C, Millefiorini E, Grasso MG, Vinci F, Fiorelli M, Koudriavtseva T, Pozzilli C. Fatigue in MS associated with specific clinical features. Acta Neurol. Scand. 1995; 92: 353-352. Go to original source... Go to PubMed...
    7. Heesen C, Nawrath L, Reich C, Bauer N, Schulz KH, Gold SM. Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour? J Neurol Neurosurg Psychiatry 2006 Jan; 77(1): 34-39. Go to original source...
    8. Roelcke U, Kappos L, Lechner-Scott J, et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997; 48: 1566-1571. Go to original source... Go to PubMed...
    9. Tellez N, Alonso J, Rio J, et al. The basal ganglia: a substrate for fatigue in multiple sclerosis. Neuroradiology 2008; 50: 17-23. Go to original source...
    10. Gottschalk M, Kümpfel T, Flachenecker P, Uhr M, Trenkwalder C, Holsboer F, Weber F. Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. Arch Neurol. 2005 Feb; 62(2): 277-280. Go to original source...
    11. Manconi M, Fabbrini M, Bonanni E, Filippi M, Rocca M, Murri L, Ferini-Strambi L. High prevalence of restless legs syndrome in multiple sclerosis. Eur J Neurol. 2007 May; 14(5): 534-539. Go to original source...
    12. Merlino G, Fratticci L, Lenchig C, Valente M, Cargnelutti D, Picello M, Serafini A, Dolso P, Gigli GL. Prevalence of 'poor sleep' among patients with multiple sclerosis: an independent predictor of mental and physical status. Sleep Med. 2009 Jan; 10(1): 26-34. Go to original source... Go to PubMed...
    13. Fisk JD, Pontefract A, Ritvi PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis Can J Neurol. Sci 1994; 21: 9-14. Go to original source... Go to PubMed...
    14. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989; 46: 1121-1123. Go to original source...
    15. Tellez N, Rio J, Tintore M, Nos C, Galan I, Montalban X. Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS? Mult Scler. 2005; 11: 198-202. Go to original source... Go to PubMed...
    16. Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil 1984; 65: 135-138.
    17. Petajan JH, Gappmaier E, White AT, Spencer MK, MinoL, Hicks RW. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann. Neurol. 1996; 39: 432-441. Go to original source...
    18. Freal JF, Kraft GH, Coryell JK. Symptomatic fatique in MS. Arch. Phys. Med. Rehabil. 1984; 165: 135-138.
    19. Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, Halper J, Johnson B, Morgante L, Grimson R. Fatigue therapy in multiple sclerosis: results of a double blind, randomized, parallel trial of amantadine, pemoline and placebo. Neurology 1995; 45: 1956-1961. Go to original source... Go to PubMed...
    20. Rosenberg GA, Appenzeller O. Amantadine, fatigue, and multiple sclerosis. Arch. Neurol. 1988; 45: 1104-1106. Go to original source... Go to PubMed...
    21. The Canadian MS Research Group. A randomized controlled trial of amantadin in fatigue associated with multiple sclerosis. Can. J. Neurol. Sci. 1987; 14: 273-278. Go to original source...
    22. Taus C, Giuliani G, Pucci E, D'Amico R, Solari A. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2003. Go to original source...
    23. Weinshenker BG, Penman M, Bass B, Ebers GC, Rice GP. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992; 42: 1468-1471. Go to original source...
    24. Vercoulen JHMM, Swanink CMA, Zitman FG, et al. 1996b. Randomized, double blind, placebo-controlled study of fluoxetin in chronic fatique syndrome. Lancet 347: 858-861. Go to original source...
    25. Scott T, Nussbaum P, McConnell H, et al. Measurement of treatment response to sertraline in depressed multiple sclerosis patient using The Carroll Scale. Neurology Research 1996; 7: 421-422. Go to original source...
    26. Putzki N, Yaldizli O, Tettenborn B, Diener HC. Multiple sclerosis associated fatigue during natalizumab treatment. J Neurol Sci. 2009 Oct 15; 285(1-2): 109-113. Go to original source...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.